ImmuneBridge
SAN FRANCISCO, CA · Biotechnology · 19 employees
ImmuneBridge is developing allogeneic immunotherapies for cancer. Our core technology drives the expansion of cord blood derived immune stem cells and establishes a novel, flexible, consistent and abundant cellular source for immunotherapies. We are currently pursuing natural killer cell products for hematological malignancies. Next we will use the unique advantages of our cellular source to tackl
Funding history
- Funding Round — $5.6M — Apr 2025
- Funding Round — $10.2M — Jan 2023
Recent signals
- Mar 24, 2026: ImmuneBridge Promotes Dr. Nina Horowitz to CEO and Appoints Dr. Rui Tostoes as Chief Technology Officer
- Apr 02, 2025: Raised $5.6M
- Jan 10, 2023: Raised $10.2M
See plans & pricing → Track ImmuneBridge’s funding, hiring, and signals — with verified contacts — on Fundz.